Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2003

View Archived Issues

Company Profile: Adventrx Pharmaceuticals

Melatonin as a novel therapy for Alzheimer's disease

Beta-L-2'-Fd4C shows antiviral activity and favorable pharmacokinetics in HBV

Sulphamoylated estrogen derivatives show potential in treating drug-resistant breast cancer

Yamanouchi and GlaxoSmithKline to copromote Vesicare in U.S.

Enrollment opens in phase II trial of Tarceva in malignant glioma

Phase II trial preparations advance for Norwood Immunology technology

Incara selects AEOL-10150 as candidate for ALS

FDA approves Trileptal for children

Paratek claims non-antibacterial tetracyclines for cancer, stroke and lung injury

Novel antibacterial tetracyclines in Paratek development pipeline

Receptor tyrosine kinase inhibitors and their use reported by Theravance

Novel 5-HT2C receptor ligands and their use as antiobesity agents

Novel series of Syk kinase inhibitors covered by Boehringer Ingelheim patent

Phase II DCF-987 trial completes enrollment

Ceregene acquires rights to ALS gene therapy from Salk Institute

ViroPharma acquires maribavir rights from GlaxoSmithKline

FDA Advisory Committee schedules review of Metvix for basal cell carcinoma

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Caprion and AstraZeneca collaborate on pain biomarker research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...